天津医药 ›› 2016, Vol. 44 ›› Issue (1): 75-78.doi: 10.11958/59076

• 临床研究 • 上一篇    下一篇

核糖体蛋白L6 在前列腺癌中的表达及临床意义

张蒙, 盛镔, 马鹏德, 张昌文, 徐勇△   

  1. 天津医科大学第二附属医院、 天津市泌尿外科研究所 (邮编300211)
  • 收稿日期:2015-06-10 修回日期:2015-08-23 出版日期:2016-01-15 发布日期:2016-01-15
  • 通讯作者: △通讯作者 E-mail:xuyongprof@163.com E-mail:zhangmon0811@163.com
  • 作者简介:张蒙 (1990), 男, 硕士在读, 主要从事前列腺癌的基础与临床研究
  • 基金资助:
     天津市应用基础及前沿技术研究计划(12JCYBJC31400)

Expression and clinical significance of ribosomal protein L6 in prostate cancer

ZHANG Meng, SHENG Bin, MA Pengde, ZHANG Changwen, XU Yong△   

  1. The Second Affiliated Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China
  • Received:2015-06-10 Revised:2015-08-23 Published:2016-01-15 Online:2016-01-15
  • Contact: △Corresponding Author E-mail:xuyongprof@163.com E-mail:zhangmon0811@163.com

摘要: 摘要:目的 探讨核糖体蛋白 L6 (RPL6) 在前列腺癌组织中的表达及临床意义。方法 应用实时荧光定量 PCR (RT-qPCR) 和 Western blot 检测 RPL6 在前列腺癌组织 (80 例) 及癌旁组织 (62 例) 中的表达水平, 分析 RPL6 mRNA 表达水平与前列腺癌患者的临床病理特征及预后之间的关系。结果 RPL6 在前列腺癌组织中的表达水平明显高于癌旁组织(P < 0.05); 血清前列腺特异性抗原 (PSA) 值高、 Gleason 评分高、 临床分期晚、 有淋巴结转移患者的 RPL6 mRNA 表达水平增高 (均 P < 0.05), 而不同年龄、 精囊侵袭、 血管侵犯及手术切缘阳性情况患者的 RPL6 mRNA 表达水平无明显差异(均 P > 0.05)。 RPL6 mRNA 高表达前列腺癌患者的术后无生化复发生存率较低 (χ2 =4.530,P= 0.033)。结论 RPL6 表达水平增高与前列腺癌的发生发展及不良预后相关; 或可用其作为初步判断前列腺癌患者预后的肿瘤标志物。

关键词: 核糖体蛋白 L6, 前列腺癌, 实时荧光定量PCR, 预后

Abstract: Abstract: Objective To explore the expression of ribosomal protein L6 (RPL6) in prostate cancer and its clinical sig⁃ nificance. Methods RT-qPCR and Western blot assay were used to measure the mRNA transcription and protein expres⁃ sion levels of RPL6 in prostate cancer tissues (n=80) and adjacent non-cancerous tissues (n=62). The relationship between RPL6 mRNA expression level and clinicopathological factors of prostate cancer was statistically analyzed. Results The mRNA and protein expression levels of RPL6 were significantly higher in prostate cancer tissues compared with those of non-cancerous tissues (P < 0.05). There were higher serum expression levels of prostate specific antigen (PSA) and higher Gleason score in prostate cancer tissues. The expression level of RPL6 mRNA was significantly higher in patients with lymph node metastasis and late clinical stage (P < 0.05). There were no significant differences in PSA levels between different ages, with or without seminal vesicle invasion and different surgical margin status (P > 0.05). Kaplan-Meier survival analysis of biochemical recurrence (BCR)-free survival time showed the significantly lower recurrent rate in patients with high RPL6 mRNA expression (χ2 =4.530,P=0.033). Conclusion The elevated expression of RPL6 may play a role in the development of prostate cancer, and which can be used as a tumor marker to assess the prognosis of prostate cancer.

Key words: ribosomal protein L6, prostate cancer, real-time quantitative PCR, prognosis